NCT07193459View on ClinicalTrials.gov

Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

October 10, 2026

Study Completion Date

February 1, 2027

Conditions
Type 2 Diabetes
Interventions
DRUG

HDM1002 200 mg

HDM1002 tablets, 200 mg once daily

DRUG

HDM1002 400 mg

HDM1002 tablets, 400 mg once daily

DRUG

Placebo

Placebo tablets, once daily

Trial Locations (1)

100000

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT07193459 - Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter